- +1-315-215-1633
- sales@thebrainyinsights.com
The global liver fibrosis market is growing at a CAGR of 10.96% and valued at USD 17.25 billion in 2021 projected to reach USD 43.98 billion by 2030. North America is expected to grow the fastest during the forecast period. Liver fibrosis is an inefficient wound-healing process of the liver in response to repeated and chronic injury from many etiologies, such as exposure to toxins (e.g., alcohol liver diseases), metabolic derangements (nonalcoholic steatohepatitis), infectious diseases (e.g., viral hepatitis), or autoimmune diseases (e.g., primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis). Liver fibrosis results from chronic damage to the liver in conjunction with the collection of ECM proteins, a characteristic of most chronic liver diseases. The primary causes of liver fibrosis in industrialized countries are nonalcoholic steatohepatitis (NASH), chronic HCV infection, and alcohol abuse. Further, the COVID-19 pandemic negatively impacted the global liver fibrosis market due to the decreased demand for drugs used in liver treatment.
The liver is an essential organ of the human body that performs vital functions like storing vitamins & nutrients, removing harmful substances from the blood, and keeping an adequate balance of chemicals in the body. Liver fibrosis is the excessive accumulation of extracellular matrix proteins containing collagen, which occurs in most types of chronic liver diseases. The primary cause of chronic liver fibrosis & diseases is hepatitis virus infections like CHC and CHB. Thus, anti-hepatitis virus therapy plays a vital role in treating liver fibrosis. Currently, the prominent drugs for the treatment of CHB are nucleotide analogs and interferon. The morphology features of liver fibrosis are the deposition of extracellular matrix (ECM) that myofibroblasts produce. Myofibroblasts are absent from the healthy liver, gather in the injured liver, and act as the principal effector cells of fibrogenesis.
Get an overview of this study by requesting a free sample
Drivers:
The increasing prevalence of liver fibrosis across the world: The surging prevalence of risk factors such as chronic hepatitis C or B infection, a weakened immune system owing to HIV co-infection, or the usage of immunosuppressive medicines after a liver transplant is the driving factor of the market growth. Further, the increasing prevalence of liver fibrosis worldwide also propels the market growth. Moreover, the growing investment in healthcare infrastructure, significant development in the healthcare industry, and the implementation of different government initiatives to promote public health are helping to boost market growth during the forecast period.
Resraints:
The high cost associated with the treatment: The absence of skilled professionals & the lack of healthcare infrastructure in developing economies is the restraining factor in the market. Moreover, the high price associated with the treatment and execution of stringent government regulations hampers market growth. Further, the low screening rate of patients and the lack of awareness about treatment are also expected to hinder the market growth during the forecast period.
Opportunities:
The growing investment in the development of advanced technologies: The increase in emerging industries and the increasing investment in developing advanced technologies are opportunities for market growth. Further, an increase in the number of R&D activities along with the rising drug approvals & launches is propelling the market growth during the forecast period. In addition, the rise in government-driven initiatives in liver cirrhosis treatment is also helping to drive market growth.
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the largest market for the global liver fibrosis market, with a 43.56% share of the market revenue in 2021. North America dominates the liver fibrosis market due to innovative drug molecules enhancing the treatment procedure and technological advancements. Further, the rise in prevalence of liver diseases & healthcare expenditure, the presence of key players, and the high R&D investments are driving the market growth in this region. In addition, the favorable reimbursement scenario, the rise in awareness about new treatment options, and the developed regulatory framework are the driving factor of the market growth in this region. In addition, the Asia Pacific is expected to grow the fastest during the forecast period due to the growing prevalence of chronic liver diseases like nonalcoholic fatty liver disease, hepatitis, and others. Further, rapidly developing economies and evolving healthcare infrastructure also propel market growth in this region. Moreover, the growing medical tourism industry and increasing disposable income drive market growth. In addition, the non-government and government awareness programs related to liver disease are also helping to boost market growth.
North America Region Liver Fibrosis Market Share in 2021 - 43.56%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
Treatment segment analysis
The treatment segment is divided into hepatotropic drugs, ACE inhibitors, peroxisome proliferator-activated receptors (PPAR)-alpha agonist, and others. The hepatotropic drug segment dominated the market, with a market share of 29.16% in 2021. This growth is attributed to the increasing awareness of new drugs. Further, hepatitis is a medical condition where the liver is predominantly affected, further infecting the digestive system and brain in the long term. There are three significant types of hepatitis conditions – HCV, HBV, and HAV. HCV is a significant public health problem where the liver gets inflamed due to infection.
Condition segment analysis
The condition segment is divided into hepatitis C, chronic liver diseases, and nonalcoholic steatohepatitis. The hepatitis C segment dominated the market, with a market share of 41.12% in 2021. This growth is attributed to the participation of multiple companies in developing treatments and medications. Further, the rising number of government initiatives, along with the increasing awareness about treating hepatitis C, are also helping to propel the segment's market growth.
Diagnosis segment analysis
The diagnosis segment is divided into nonsurgical tests, liver biopsy, transient elastography, and others. In 2021, the liver biopsy segment dominated the market with the largest market share of 31.02% and market revenue of 5.35 billion. This growth is attributed to the increasing government support for research & development.
Distribution Channel segment analysis
The distribution channel segment is divided into retail pharmacy, hospital pharmacy, online pharmacy, and others. In 2021, the hospital pharmacy segment dominated the market, accounting for around 32.05% of global revenue. This growth is attributed to the increasing awareness amongst pharmacists.
End-user segment analysis
The end-user segment is divided into specialty clinics, hospitals, homecare, and others. In 2021, the hospitals' segment dominated the market, accounting for around 28.34% of global revenue. This growth is attributed to the increasing prevalence of lifestyle diseases.
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2021 | USD 17.25 Billion |
| Market size value in 2030 | USD 43.98 Billion |
| CAGR (2022 to 2030) | 10.96% |
| Historical data | 2019-2020 |
| Base Year | 2021 |
| Forecast | 2022-2030 |
| Segments | Treatment, condition, diagnosis, distribution channel, end-user, and regions |
| Regional Segments | Europe, Asia Pacific, North America, South America, and Middle East & Africa. |
As per The Brainy Insights, the size of the liver fibrosis market was valued at USD 17.25 billion in 2021 to USD 43.98 billion by 2030.
Global liver fibrosis market is growing at a CAGR of 10.96% during the forecast period 2022-2030.
North America region emerged as the largest market for the liver fibrosis.
Key players are Mylan N.V., F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Sanofi, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Vertex Pharmaceuticals Incorporated
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By Treatment
4.3.2. Market Attractiveness Analysis By Condition
4.3.3. Market Attractiveness Analysis By Diagnosis
4.3.4. Market Attractiveness Analysis By Distribution Channel
4.3.5. Market Attractiveness Analysis By End-User
4.3.6. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. The increasing prevalence of liver fibrosis across the world
5.2.2. The growing investment in healthcare infrastructure
5.2.3. The increase in the number of emerging markets
5.2.4. Surge in geriatric population
5.3. Restraints
5.3.1. The high cost associated with the treatment
5.3.2. The high investment cost of drugs particularly across the developing nations
5.4. Opportunities
5.4.1. The rising investment for the development of advanced technologies
5.4.2. The surging drug approvals & launches
1. Global Liver Fibrosis Market Analysis and Forecast, By Treatment
1.1. Segment Overview
1.2. Hepatotropic Drug
1.3. ACE Inhibitors
1.4. Peroxisome Proliferator-Activated Receptors (PPAR)-Alpha Agonist
1.5. Others
2. Global Liver Fibrosis Market Analysis and Forecast, By Condition
2.1. Segment Overview
2.2. Hepatitis C
2.3. Chronic Liver Diseases
2.4. Nonalcoholic Steatohepatitis
3. Global Liver Fibrosis Market Analysis and Forecast, By Diagnosis
3.1. Segment Overview
3.2. Nonsurgical Tests
3.3. Liver Biopsy
3.4. Transient Elastography
3.5. Others
4. Global Liver Fibrosis Market Analysis and Forecast, By Distribution Channel
4.1. Segment Overview
4.2. Retail Pharmacy
4.3. Hospital Pharmacy
4.4. Online Pharmacy
4.5. Others
5. Global Liver Fibrosis Market Analysis and Forecast, By End-User
5.5. Segment Overview
5.6. Specialty Clinics
5.7. Hospitals
5.8. Homecare
5.9. Others
6. Global Liver Fibrosis Market Analysis and Forecast, By Regional Analysis
6.1. Segment Overview
6.2. North America
6.2.1. U.S.
6.2.2. Canada
6.2.3. Mexico
6.3. Europe
6.3.1. Germany
6.3.2. France
6.3.3. U.K.
6.3.4. Italy
6.3.5. Spain
6.4. Asia-Pacific
6.4.1. Japan
6.4.2. China
6.4.3. India
6.5. South America
6.5.1. Brazil
6.6. Middle East and Africa
6.6.1. UAE
6.6.2. South Africa
7. Global Liver Fibrosis Market-Competitive Landscape
7.1. Overview
7.2. Market Share of Key Players in Global Liver Fibrosis Market
7.2.1. Global Company Market Share
7.2.2. North America Company Market Share
7.2.3. Europe Company Market Share
7.2.4. APAC Company Market Share
7.3. Competitive Situations and Trends
7.3.1. Product Launches and Developments
7.3.2. Partnerships, Collaborations, and Agreements
7.3.3. Mergers & Acquisitions
7.3.4. Expansions
8. Company Profiles
8.1. Mylan N.V.
8.1.1. Business Overview
8.1.2. Company Snapshot
8.1.3. Company Market Share Analysis
8.1.4. Company Product Portfolio
8.1.5. Recent Developments
8.1.6. SWOT Analysis
8.2. F. Hoffmann-La Roche Ltd.
8.2.1. Business Overview
8.2.2. Company Snapshot
8.2.3. Company Market Share Analysis
8.2.4. Company Product Portfolio
8.2.5. Recent Developments
8.2.6. SWOT Analysis
8.3. Johnson & Johnson Private Limited
8.3.1. Business Overview
8.3.2. Company Snapshot
8.3.3. Company Market Share Analysis
8.3.4. Company Product Portfolio
8.3.5. Recent Developments
8.3.6. SWOT Analysis
8.4. Sanofi
8.4.1. Business Overview
8.4.2. Company Snapshot
8.4.3. Company Market Share Analysis
8.4.4. Company Product Portfolio
8.4.5. Recent Developments
8.4.6. SWOT Analysis
8.5. Teva Pharmaceutical Industries Ltd.
8.5.1. Business Overview
8.5.2. Company Snapshot
8.5.3. Company Market Share Analysis
8.5.4. Company Product Portfolio
8.5.5. Recent Developments
8.5.6. SWOT Analysis
8.6. Pfizer Inc.
8.6.1. Business Overview
8.6.2. Company Snapshot
8.6.3. Company Market Share Analysis
8.6.4. Company Product Portfolio
8.6.5. Recent Developments
8.6.6. SWOT Analysis
8.7. Novartis AG
8.7.1. Business Overview
8.7.2. Company Snapshot
8.7.3. Company Market Share Analysis
8.7.4. Company Product Portfolio
8.7.5. Recent Developments
8.7.6. SWOT Analysis
8.8. GlaxoSmithKline plc
8.8.1. Business Overview
8.8.2. Company Snapshot
8.8.3. Company Market Share Analysis
8.8.4. Company Product Portfolio
8.8.5. Recent Developments
8.8.6. SWOT Analysis
8.9. Merck & Co., Inc.
8.9.1. Business Overview
8.9.2. Company Snapshot
8.9.3. Company Market Share Analysis
8.9.4. Company Product Portfolio
8.9.5. Recent Developments
8.9.6. SWOT Analysis
8.10. AstraZeneca
8.10.1. Business Overview
8.10.2. Company Snapshot
8.10.3. Company Market Share Analysis
8.10.4. Company Product Portfolio
8.10.5. Recent Developments
8.10.6. SWOT Analysis
8.11. Vertex Pharmaceuticals Incorporated
8.11.1. Business Overview
8.11.2. Company Snapshot
8.11.3. Company Market Share Analysis
8.11.4. Company Product Portfolio
8.11.5. Recent Developments
8.11.6. SWOT Analysis
8.12. Sun Pharmaceutical Industries Ltd.
8.12.1. Business Overview
8.12.2. Company Snapshot
8.12.3. Company Market Share Analysis
8.12.4. Company Product Portfolio
8.12.5. Recent Developments
8.12.6. SWOT Analysis
8.13. Dicerna Pharmaceuticals, Inc.
8.13.1. Business Overview
8.13.2. Company Snapshot
8.13.3. Company Market Share Analysis
8.13.4. Company Product Portfolio
8.13.5. Recent Developments
8.13.6. SWOT Analysis
8.14. Bristol-Myers Squibb Company
8.14.1. Business Overview
8.14.2. Company Snapshot
8.14.3. Company Market Share Analysis
8.14.4. Company Product Portfolio
8.14.5. Recent Developments
8.14.6. SWOT Analysis
8.15. Gilead Sciences, Inc.
8.15.1. Business Overview
8.15.2. Company Snapshot
8.15.3. Company Market Share Analysis
8.15.4. Company Product Portfolio
8.15.5. Recent Developments
8.15.6. SWOT Analysis
8.16. Dynavax Technologies
8.16.1. Business Overview
8.16.2. Company Snapshot
8.16.3. Company Market Share Analysis
8.16.4. Company Product Portfolio
8.16.5. Recent Developments
8.16.6. SWOT Analysis
8.17. Pharmaxis Ltd
8.17.1. Business Overview
8.17.2. Company Snapshot
8.17.3. Company Market Share Analysis
8.17.4. Company Product Portfolio
8.17.5. Recent Developments
8.17.6. SWOT Analysis
8.18. FibroGen, Inc.
8.18.1. Business Overview
8.18.2. Company Snapshot
8.18.3. Company Market Share Analysis
8.18.4. Company Product Portfolio
8.18.5. Recent Developments
8.18.6. SWOT Analysis
List of Table
1. Global Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
2. Global Hepatotropic Drug, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
3. Global ACE Inhibitors, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
4. Global Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
5. Global Others, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
6. Global Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
7. Global Hepatitis C, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
8. Global Chronic Liver Diseases, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
9. Global Nonalcoholic Steatohepatitis, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
10. Global Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
11. Global Nonsurgical Tests, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
12. Global Liver Biopsy, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
13. Global Transient Elastography, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
14. Global Others, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
15. Global Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
16. Global Retail Pharmacy, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
17. Global Hospital Pharmacy, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
18. Global Online Pharmacy, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
19. Global Others, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
20. Global Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
21. Global Specialty Clinics, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
22. Global Hospitals, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
23. Global Homecare, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
24. Global Others, Liver Fibrosis Market, By Region, 2019-2030 (USD Billion)
25. North America Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
26. North America Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
27. North America Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
28. North America Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
29. North America Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
30. U.S. Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
31. U.S. Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
32. U.S. Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
33. U.S. Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
34. U.S. Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
35. Canada Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
36. Canada Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
37. Canada Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
38. Canada Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
39. Canada Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
40. Mexico Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
41. Mexico Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
42. Mexico Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
43. Mexico Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
44. Mexico Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
45. Europe Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
46. Europe Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
47. Europe Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
48. Europe Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
49. Europe Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
50. Germany Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
51. Germany Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
52. Germany Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
53. Germany Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
54. Germany Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
55. France Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
56. France Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
57. France Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
58. France Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
59. France Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
60. U.K. Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
61. U.K. Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
62. U.K. Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
63. U.K. Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
64. U.K. Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
65. Italy Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
66. Italy Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
67. Italy Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
68. Italy Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
69. Italy Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
70. Spain Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
71. Spain Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
72. Spain Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
73. Spain Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
74. Spain Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
75. Asia Pacific Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
76. Asia Pacific Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
77. Asia Pacific Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
78. Asia Pacific Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
79. Asia Pacific Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
80. Japan Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
81. Japan Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
82. Japan Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
83. Japan Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
84. Japan Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
85. China Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
86. China Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
87. China Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
88. China Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
89. China Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
90. India Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
91. India Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
92. India Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
93. India Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
94. India Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
95. South America Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
96. South America Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
97. South America Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
98. South America Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
99. South America Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
100. Brazil Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
101. Brazil Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
102. Brazil Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
103. Brazil Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
104. Brazil Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
105. Middle East and Africa Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
106. Middle East and Africa Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
107. Middle East and Africa Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
108. Middle East and Africa Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
109. Middle East and Africa Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
110. UAE Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
111. UAE Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
112. UAE Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
113. UAE Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
114. UAE Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
115. South Africa Liver Fibrosis Market, By Treatment, 2019-2030 (USD Billion)
116. South Africa Liver Fibrosis Market, By Condition, 2019-2030 (USD Billion)
117. South Africa Liver Fibrosis Market, By Diagnosis, 2019-2030 (USD Billion)
118. South Africa Liver Fibrosis Market, By Distribution Channel, 2019-2030 (USD Billion)
119. South Africa Liver Fibrosis Market, By End-User, 2019-2030 (USD Billion)
List of Figures
1. Global Liver Fibrosis Market Segmentation
2. Global Liver Fibrosis Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Liver Fibrosis Market Attractiveness Analysis By Treatment
9. Global Liver Fibrosis Market Attractiveness Analysis By Condition
10. Global Liver Fibrosis Market Attractiveness Analysis By Diagnosis
11. Global Liver Fibrosis Market Attractiveness Analysis By Distribution Channel
12. Global Liver Fibrosis Market Attractiveness Analysis By End-User
13. Global Liver Fibrosis Market Attractiveness Analysis By Region
14. Global Liver Fibrosis Market: Dynamics
15. Global Liver Fibrosis Market Share By Treatment (2022 & 2030)
16. Global Liver Fibrosis Market Share By Condition (2022 & 2030)
17. Global Liver Fibrosis Market Share By Diagnosis (2022 & 2030)
18. Global Liver Fibrosis Market Share By Distribution Channel (2022 & 2030)
19. Global Liver Fibrosis Market Share By End-User (2022 & 2030)
20. Global Liver Fibrosis Market Share By Regions (2022 & 2030)
21. Global Liver Fibrosis Market Share By Company (2021)
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the global liver fibrosis based on below mentioned segments:
Global Liver Fibrosis Market by Treatment:
Global Liver Fibrosis Market by Condition:
Global Liver Fibrosis Market by Diagnosis:
Global Liver Fibrosis Market by Distribution Channel:
Global Liver Fibrosis Market by End-User:
Global Liver Fibrosis by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
